The PE Ratio as of December 2025 (TTM) for Rapport Therapeutics, Inc. Common Stock (RAPP) is -12.64

According to Rapport Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current PE Ratio is -12.64. This represents a change of -75.36% compared to the average of -51.30 of the last 4 quarters.

Rapport Therapeutics, Inc. Common Stock (RAPP) Historical PE Ratio (quarterly & annually)

How has RAPP PE Ratio performed in the past?

The mean historical PE Ratio of Rapport Therapeutics, Inc. Common Stock over the last ten years is -182.63. The current -12.64 PE Ratio has changed 592.09% with respect to the historical average. Over the past ten years (40 quarters), RAPP's PE Ratio was at its highest in in the March 2025 quarter at -20.10. The PE Ratio was at its lowest in in the March 2023 quarter at -164.60.

Rapport Therapeutics, Inc. Common Stock (RAPP) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Rapport Therapeutics, Inc. Common Stock PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Rapport Therapeutics, Inc. Common Stock (RAPP) Average PE Ratio

How has RAPP PE Ratio performed in the past?

The current PE Ratio of Rapport Therapeutics, Inc. Common Stock (RAPP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Rapport Therapeutics, Inc. Common Stock (RAPP) PE Ratio vs. Peers

How is RAPP’s PE Ratio compared to its peers?

Rapport Therapeutics, Inc. Common Stock’s PE Ratio is less than Nurix Therapeutics, Inc. (-6.20), less than Kodiak Sciences Inc. (-8.40), less than Phathom Pharmaceuticals, Inc. (-3.93), less than Xencor, Inc. (-7.58), less than BridgeBio Oncology Therapeutics Inc. (-2.36), greater than AnaptysBio, Inc. (-14.24), less than Mind Medicine (MindMed) Inc. (-6.35), less than UroGen Pharma Ltd. (-7.48), less than Oculis Holding AG (-7.70), greater than Septerna, Inc. (-19.73),

Build a custom stock screener for Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rapport Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rapport Therapeutics, Inc. Common Stock (RAPP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rapport Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.